Clinical Trial Update: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

View source ↗

Summary

Olaratumab has been approved for marketing for soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Olaratumab (olaratumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Soft Tissue Sarcoma | Status: APPROVED_FOR_MARKETING